News & Updates
Filter by Specialty:
MDT without ADT delays systemic therapy initiation in recurrent prostate cancer
21 Nov 2022
byStephen Padilla
In patients with solitary metastatic recurrences of prostate cancer, metastasis-directed therapy (MDT without androgen deprivation therapy (ADT) can lead to delayed initiation of systemic therapy, according to a study.
MDT without ADT delays systemic therapy initiation in recurrent prostate cancer
21 Nov 2022Cell-cycle progression tied to metastasis-free survival in high-risk prostate cancer
17 Nov 2022
Cell-cycle progression, but not phosphatase and tensin homolog, appears to significantly elevate the risk of metastasis in men with prostate cancer following Cancer of the Prostate Risk Assessment Post-Surgical adjustment, suggests a study.